SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
294 40 0 TRIL
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
69Tuck: Any comments on today’s TRIL PR re: latest CD47 results? It confirms sometuck-2/24/2017
68Tuck: Any comments on today’s TRIL PR re: latest CD47 results? Peace & good BulbaMan-2/24/2017
67Effects of TTI-621 (SIRPaFc) on CD47 and serum cytokines associated with phagocytuck-2/22/2017
66Thank you! Yes, I learned of the G4 construct some time ago. Thanks. >>scaram(o)uche-2/20/2017
65TTI-621 (SIRPaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broadtuck-2/16/2017
64Synergy with PD-L1 Durable antitumor responses to CD47 blockade require adaptivtuck-12/5/2016
63Sorry, thought that last article was a freebie, but it's not. Parsing it motuck-12/5/2016
62MYC regulates the antitumor immune response through CD47 and PD-L1 My understantuck-12/5/2016
61Clunked at ASH so far. Dose reduction. Hard to say if efficacy is drastically tuck-11/3/2016
60[X] #Trillium$TRIL +1.40 (+10.29%) Trillium Therapeutics Advances TTI-621 Into SI Ron (Crazy Music Man)-11/2/2016
59BET inhibitor update: Another player I found is in the optimization stage: Epituck-10/28/2016
58Forty Seven data, hope these links work..... pbs.twimg.com pbs.twimg.com Hemascaram(o)uche-9/28/2016
57pointer from Biomaven..... cell.comscaram(o)uche-9/26/2016
56in-house, in vitro model (apologies for having lost sight of twitter pointer)...scaram(o)uche-9/26/2016
55>> asked by the company to change its business description in the subject scaram(o)uche-9/20/2016
54I was asked by the company to change its business description in the subject heatuck-9/19/2016
53Biomaven, kicking in with good stuff...... Message 30732925scaram(o)uche-9/7/2016
52I guess that Tioma and Forty Seven could be looking for agonists as well as blocscaram(o)uche-9/7/2016
51Proc Natl Acad Sci U S A. 2016 Aug 30. pii: 201521069. [Epub ahead of print] Cdscaram(o)uche-9/7/2016
50Sounds like a cool idea, perhaps rather flattering to tril. Peter pointed to itscaram(o)uche-8/16/2016
49A couple of fresh-off-press teasers..... Sci Transl Med. 2016 Aug 10;8(351):351scaram(o)uche-8/12/2016
48atherogenesis is associated with upregulation of CD47...... ncbi.nlm.nih.gov Mscaram(o)uche-8/1/2016
47High Affinity Sirp-Alpha Reagents This is from Weissman's Stanford lab, ltuck-7/3/2016
46pbs.twimg.com pointer from @fbosomscaram(o)uche-6/10/2016
45Really hard, my scan, to find anything discouraging in the CD47 literature. Quescaram(o)uche-6/1/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News